Immunotherapy for HER-2 positive breast cancer
Source : https://www.frontiersin.org/articles/10.3389/fonc.2023.1097983/full
Immunotherapy is a developing treatment for advanced breast cancer. Immunotherapy has clinical significance for the treatment of triple-negative breast cancers and human epidermal growth factor receptor-2 positive (HER2+) breast cancers....
Conclusions/Relevance: Adoptive T-cell immunotherapies and tumor vaccines are emerging as novel approaches to treating breast cancer, but require further study. This article reviews recent advances in immunotherapy for HER2+ breast cancers.
-
Albert Dekker3yrwill see how it works out; so far best outcomes are still in renal and melanoma
Single oral dose acute and subacute toxicity of a c-MET tyrosine kinase inhibitor and CDK 4/6 inhibitor combination drug therapy
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5794732/
c-MET inhibitor, crizotinib, and CDK 4/6 inhibitor, palbociclib, have been evaluated in combination as cancer treatment in vitro. Because the toxicological data for the combination of these drugs is limited,...
Conclusions/Relevance: The findings from the current in vivo toxicity study in mice, which encompassed two time points at 24 hours and 7 days, may help build upon the base knowledge of what is already known in reference to C and P and provide helpful information for future studies of these drugs. We have shown that the combination of C and P...
Individualizing Curative-Intent Therapy in HER2-Positive Early-Stage Breast Cancer - Current Treatment Options in Oncology
Source : https://link.springer.com/article/10.1007/s11864-023-01070-7
Human epidermal growth factor receptor 2-positive (HER2+) breast cancers have been historically considered an aggressive entity with high rates of recurrence and poor survival. However, during the last 20 years,...
Opinion Statement: Various biomarkers have been proposed to better characterize the clinical and biological heterogeneity of HER2+ breast cancer. Immune infiltration, intrinsic subtype, intratumoral heterogeneity, and dynamic changes during treatment have been described as important prognostic and/or predictive features. The integration of...
CDK4/6 Inhibitors-Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36980649/
Achieving significant improvements in survival rates in the advanced and early breast cancer treatment setting, CDK4/6 inhibitors have set a new standard of care for patients with advanced breast cancer....
Summary: Achieving significant improvements in survival rates in the advanced and early breast cancer treatment setting, CDK4/6 inhibitors have set a new standard of care for patients with advanced breast cancer. It remains important to better understand resistance mechanisms to be able to develop novel substances and treatment...
Virtual Screening for Identification of Dual Inhibitors against CDK4/6 and Aromatase Enzyme - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36985460/
CDK4/6 and aromatase are prominent targets for breast cancer drug discovery and are involved in abnormal cell proliferation and growth. Although aromatase inhibitors have proven to be effective (for example...
Conclusions/Relevance: Molecular dynamics simulation studies solidify the stability of the lead candidate complexes. In addition, ADMET and DFT calculations bolster the lead candidates. Hence, these combined computational approaches will provide a better therapeutic potential for developing CDK4/6-aromatase dual inhibitors for HR+ breast...